Moreover we and others[19,22,23] showed that HER2 is expressed from 39% to 56.3% and is a negative prognostic factor[23] similar to human breast cancer (20-30%)[24] while Rasotto and colleagues[25] demonstrated that only the 5.5% of FMCs was HER2 positive and it is not a prognostic factor in FMCs. This evidence concerns the gene ERBB2 and breast carcinoma.